Novartis "buy"

11.07.06 - Jyske Bank

LONDON, July 11 (newratings.com) - Analysts at Jyske Bank maintain their "buy" rating on Novartis (NOT). The target price is set to CHF85.

In a research note dated July 10 and published this morning, the analysts mention that there has been a continued healthy development in the company's pharmaceutical business, boosted by the sale of key products. Novartis has several new products that may be launched shortly, Jyske Bank adds.